Peptides for Hair Growth

7 research peptides are currently studied for hair growth. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

AHK (Alanyl-Histidyl-Lysine) is a tripeptide that shares structural similarities with GHK, particularly in its ability to bind copper. This copper-binding property is thought to enhance its biological activity, particularly in promoting hair follicle growth and facilitating wound healing through mechanisms such as collagen synthesis and the upregulation of growth factors. Despite its promising theoretical basis, the evidence supporting AHK's efficacy is primarily derived from in vitro studies and animal models, which limits its application in human contexts. The current evidence rating for AHK is categorized as D, indicating that further research is necessary to establish its effectiveness and safety in hair growth applications.

AHK-Cu, the copper-complexed variant of AHK, is designed to enhance the peptide's biological activity, particularly in the context of hair growth and wound healing. The presence of copper is believed to play a crucial role in stimulating dermal papilla cells, which are essential for hair follicle development. Although AHK-Cu is included in various topical cosmetic formulations, the current evidence supporting its efficacy remains limited to preclinical studies. As a result, it is classified with an evidence rating of D. The potential for AHK-Cu to outperform AHK alone in promoting hair growth is an area of ongoing research, but definitive conclusions regarding its effectiveness in humans have yet to be established.

PTD-DBM is a novel, cell-permeable peptide that has garnered attention for its ability to activate the Wnt/β-catenin signaling pathway, a critical regulator of hair follicle development and cycling. Preclinical studies have demonstrated that topical application of PTD-DBM can promote new hair growth in murine models by stimulating dermal papilla cells. This peptide-based approach represents a significant departure from traditional treatments for androgenetic alopecia, such as finasteride, which primarily target hormonal pathways. Despite its innovative mechanism, the evidence supporting PTD-DBM remains in the preclinical stage, leading to an evidence rating of D. Further studies are required to assess its potential efficacy and safety in human subjects.

Acetyl Tetrapeptide-3 is a biomimetic peptide frequently utilized in hair care formulations, notably in products containing Capixyl, which combines this peptide with biochanin A derived from red clover. Manufacturer-sponsored studies have reported a 17% increase in hair diameter and a 46% reduction in hair loss over a 12-week period of topical application. Although these results are promising, they are derived from studies sponsored by the manufacturers, which may introduce bias. Acetyl Tetrapeptide-3 is classified as a cosmetic ingredient rather than a pharmaceutical drug, and its availability in various hair serums and topical products reflects its growing popularity. However, independent validation through rigorous clinical trials is necessary to substantiate these findings and establish its safety and efficacy profile.

Astressin-B is a synthetic cyclic peptide that acts as an antagonist to corticotropin-releasing factor (CRF) receptors. Originally developed for research focused on stress-related disorders, it gained unexpected attention following a 2011 study by the Salk Institute, which found that a single injection of Astressin-B could reverse hair loss in mice subjected to chronic stress. This serendipitous discovery highlighted the potential role of stress in hair loss, although the study was primarily designed to investigate gastrointestinal effects related to stress. Despite the intriguing findings, no human clinical trials have yet been conducted to explore the peptide's efficacy in hair growth. Furthermore, the troubled clinical development history of CRF antagonists in psychiatric applications raises concerns about the feasibility of translating these findings to human use. The evidence for Astressin-B's effects on hair growth is currently rated as D.

Myristoyl pentapeptide-17 is a synthetic lipopeptide commonly incorporated into cosmetic formulations aimed at enhancing eyelash and eyebrow growth. The proposed mechanism of action involves the stimulation of keratin gene expression within hair follicle cells, potentially leading to improved hair growth. The addition of a myristoyl (C14 fatty acid) chain is believed to facilitate deeper penetration into the hair follicles, thereby enhancing its efficacy. However, the clinical evidence supporting these claims remains sparse, primarily relying on studies conducted by manufacturers, which raises questions regarding the objectivity of the findings. As such, while myristoyl pentapeptide-17 is marketed for its ability to promote eyelash and eyebrow growth and to stimulate keratin production, the lack of independent validation limits its credibility within the scientific community.

Biotinoyl tripeptide-1 is a peptide composed of the GHK (glycyl-histidyl-lysine) tripeptide linked to biotin (vitamin B7), commonly found in hair care products. It is often included in formulations such as the Procapil complex, which combines biotinoyl tripeptide-1 with apigenin and oleanolic acid. The peptide is purported to strengthen hair and mitigate hair loss by enhancing follicle anchoring and metabolic activity. Despite these claims, the evidence supporting biotinoyl tripeptide-1 is primarily derived from manufacturer-sponsored studies, with a notable absence of independent clinical trials. This lack of rigorous, peer-reviewed research limits the understanding of its effectiveness and safety profile, leaving its role in hair care largely anecdotal.